about
Screening for hepatocellular carcinoma: patient selection and perspectivesChronic hepatitis C - what do the new drugs offer and who should get them first?Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts.Serum autoantibody measurement for the detection of hepatocellular carcinomaModelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.Prednisolone or pentoxifylline for alcoholic hepatitis.The hepatitis C revolution part 1: antiviral treatment options.The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial.HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.Historical epidemiology of hepatitis C virus (HCV) in selected countries.Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis.The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches.Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective.In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA.The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.New metrics for the Lancet Standing Commission on Liver Disease in the UK.Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy.Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals.Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.A world without hepatitis C.Strategies to manage hepatitis C virus (HCV) disease burden.Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified.Implementation of the Lancet Standing Commission on Liver Disease in the UK.Genotype 4 and the global challenge of hepatitis C treatment.Prednisolone or Pentoxifylline for Alcoholic HepatitisWorld Gastroenterology Organisation global guidelines: diagnosis, management and prevention of hepatitis C April 2013
P50
Q30355713-0BF07467-A4E8-4B6C-8956-7DE7C78FB568Q33421570-B2DC3582-F423-40FC-9518-63585587BFE0Q33744789-688CD438-899C-43E5-A167-DCF442E0D795Q34004797-38DC62EA-FAAB-4B02-95E4-328403041898Q34028307-C8D77594-E835-4F3D-ACDA-620D1238D089Q34473050-01C76C48-75BD-43D9-8E38-9EE663BDB77BQ34500131-F629D76B-1B82-4A8E-8673-9B8495432834Q34506101-6011E1B3-DB6B-449B-A0B5-1B67488CF0B8Q35535844-08AD174B-91FF-4F97-86DA-94C70BD930A2Q38203033-268E0953-F429-414C-91A3-F52054F507EFQ38206215-EF3FCD37-90D8-4692-972B-7827E23E9B53Q38272635-FDAF607D-DE4D-428E-A6AF-BA90C038CAC0Q38622419-A305C074-B53C-48E5-97A3-F7B027132607Q38740104-A0681A9A-172C-4458-A3EB-A6B4E3AE6892Q39043880-92F1ECA7-10FA-4C9E-932E-1142391BC34FQ39213684-3087AD7E-EC74-4922-9DFA-061E96976CB9Q39595721-550C4CE3-02AF-4169-BD34-373A59F5E62CQ40539605-092866BD-E7AA-47F3-AE4B-A25E48490907Q40562865-61AF76C6-E649-468D-AF11-CE2C680BD4EEQ41633359-AEFE4773-137F-4E65-AD13-AFAEBBD06873Q42205777-06015867-436E-41B9-AEAA-6CE44857AF85Q42226125-01B8B740-0C20-4F6C-A9D0-627F6A4706A2Q42228282-72944350-9602-41E7-A76A-9A7594E9F1B6Q42252016-6A00CC29-78A1-4180-8193-9FDF2BCAFCDDQ51055847-FBFA2ED4-C8CF-4A37-A5D0-6644B6D5F7B6Q52819324-F74627F7-5096-4A96-8CD0-BFD64A674E1FQ53360397-CF4FB5FC-401C-434E-B447-6F9DE4074BEFQ85598309-ABB9E0AE-99FE-4362-80B3-06BB9D4EDF85Q87247208-E6CEFBC5-0C5F-47AD-BC7D-32E0ACEF0B24
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stephen D Ryder
@ast
Stephen D Ryder
@en
Stephen D Ryder
@es
Stephen D Ryder
@sl
type
label
Stephen D Ryder
@ast
Stephen D Ryder
@en
Stephen D Ryder
@es
Stephen D Ryder
@sl
altLabel
Stephen Ryder
@en
prefLabel
Stephen D Ryder
@ast
Stephen D Ryder
@en
Stephen D Ryder
@es
Stephen D Ryder
@sl
P106
P21
P31
P496
0000-0001-9649-4444